IMAC Holdings, Inc. Appoints Jeffrey Busch to Serve as Chairman
May 23, 2023 at 08:30 am EDT
Share
Theralink Technologies, Inc. and IMAC Holdings, Inc. announced that they have entered into a definitive Agreement and Plan of Merger (the "Merger Agreement") under which Theralink will merge with a newly-formed wholly-owned subsidiary of IMAC in a stock-for-stock reverse merger transaction (the "Merger") in which Theralink will survive as a wholly-owned subsidiary of IMAC, a Nasdaq-listed company. If completed, the Merger will result in a combined company that will focus on end-to-end proteomics testing, one of the most robust and growing areas of medicine. All current IMAC directors but one will resign effective upon the closing of the Merger, and the existing directors of Theralink shall be appointed to the board of IMAC, with Jeffrey Busch to serve as Chairman.
IMAC Holdings, Inc. owns and manages health and wellness centers that delivers sports medicine, orthopedic care, and restorative joint and tissue therapies for movement restricting pain and neurodegenerative diseases. The Company provides movement, orthopedic and neurological therapies through its chain of Innovative Medical Advancements and Care (IMAC) Regeneration Centers. The Company, through its outpatient medical clinics, provide conservative, minimally invasive medical treatments to help patients with back pain, knee pain, joint pain, ligament and tendon damage, and other related soft tissue conditions. It operates through two business segments: outpatient medical centers and clinical research division. The Company's research division is conducting a Phase I clinical trial evaluating a mesenchymal stem cell therapy candidate for bradykinesia due to Parkinsonâs disease. The Company operates approximately 10 outpatient medical clinics in five states in the United States.
IMAC HOLDINGS, INC. 
